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Abstract
In the present study, the optimal medium perfusion rate to be used for the continuous culture of a
recombinant CHO cell line in a packed-bed bioreactor made of Fibra-Cel disk carriers was determined. A
ﬁrst-generation process had originally been designed with a high perfusion rate, in order to rapidly produce
material for pre-clinical and early clinical trials. It was originally operated with a perfusion of 2.6 vvd
during production phase in order to supply the high cell density (2.5 · 107 cell ml1 of packed-bed) with
suﬃcient fresh medium. In order to improve the economics of this process, a reduction of the medium
perfusion rate by 25% and 50% was investigated at small-scale. The best option was then implemented
at pilot scale in order to further produce material for clinical trials with an improved second-generation
process. With a 25% reduction of the perfusion rate, the volumetric productivity was maintained com-
pared to the ﬁrst-generation process, but a 30% loss of productivity was obtained when the medium
perfusion rate was further reduced to 50% of its original level. The protein quality under reduced
perfusion rate conditions was analyzed for purity, N-glycan sialylation level, abundance of dimers or
aggregates, and showed that the quality of the ﬁnal drug substance was comparable to that obtained in
reference conditions. Finally, a reduction of 25% medium perfusion was implemented at pilot scale in the
second-generation process, which enabled to maintain the same productivity and the same quality of the
molecule, while reducing costs of media, material and manpower of the production process. For industrial
applications, it is recommended to test whether and how far the perfusion rate can be decreased during the
production phase – provided that the product is not sensitive to residence time – with the beneﬁts of
reduced cost of goods and to simplify manufacturing operations.
Introduction
The biotech industry makes an extensive use of
mammalian cells for the manufacturing of re-
combinant glycoproteins for human therapy.
Today, fed-batch and perfusion cultures are the
two dominant modes of industrial operation for
the mammalian cell culture processes that require
large amount of proteins (Hu and Aunins 1997).
Whatever the production technology of choice is,
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development eﬀorts are continuously invested in
order to obtain production processes that warrant:
high volumetric productivity, batch-to-batch con-
sistency, homogenous product quality at low costs.
The decision between fed-batch or perfusion
production mode is mainly dictated by the biology
of the clone and the property of the product, and
has to be done case-by-case during the course of
the development of a new drug product (Kadouri
and Spier 1997).
When the selection is a perfusion process, one of
the culture systems of choice is stationary packed-
bed bioreactor in which cells are immobilized onto
solid carriers. This system is easy to operate and
with appropriate carriers and culture conditions
very high cell density (of 107–108 cell ml1) can
be achieved.
A consequence of this high cell density is the
need for an intensive medium perfusion rate (feed
and harvest) that should be used in order to keep
the cells viable and productive. It appears that the
perfusion rate is one of the central parameters of
such a process: it drives the volumetric protein
productivity, the protein product quality and has a
very strong impact on the overall economics of the
process.
Therefore, at industrial scale the optimal sta-
tionary packed-bed bioreactor process should
operate with a perfusion rate as low as possible
without compromising on quantity and quality of
the product.
In the course of reducing the perfusion rate,
several studies were conducted where the concen-
tration of glucose (Dowd et al. 2001; Wang et al.
2002) is used as an indicator of other nutrients
level in the feed medium in order to operate the
bioreactor at a low perfusion rate without accu-
mulating in the culture high levels of toxic by-
products such as lactate and ammonia (Racher
et al. 1993; Sugiura and Kakuzaki 1998). Modiﬁ-
cation of culture parameters such as pH or tem-
perature (Chuppa et al. 1997) is also a common
strategy to optimize culture conditions and reduce
medium perfusion needs.
In order to achieve optimal medium perfusion
rate, three approaches can be considered:
(a) To ﬁx perfusion rate at a constant value dur-
ing the entire production run. This approach
is usually preferred in industrial production
processes, since it is simpler to operate in a
robust and consistent way. It also has the
advantage to deﬁne medium costs of the
process as there is no variation in perfusion
rate from run to run.
(b) To adjust perfusion rate in response to cell
number and/or nutrient consumption such as
glucose (Oh et al. 1994; Dowd et al. 2001; Go-
renﬂo et al. 2003), glutamine (Gorenﬂo et al.
2002), or oxygen (Kyung et al. 1994). Although
this approach provides a more scientiﬁc ratio-
nale for adjusting the perfusion rate, it may
lead to an overgrown culture and an ‘out-of-
control’ increase of the perfusion rate. When
cells are cultured in suspensionmode, a ‘culture
bleed’ is done to avoid overgrowing the culture,
but this is not possible when cells are immobi-
lized ona carrier. So in general, this approach is
not preferred for manufacturing operations as
it is diﬃcult to operate in a robust and consis-
tent manner and the medium perfusion rate
needs to be readjusted on a daily basis.
(c) To combine both strategies (a) and (b) with an
initial cell propagation phase (or ‘growth
phase’) where the perfusion rate is progres-
sively increased according to cell growth
requirements during the growth phase fol-
lowed by a shift of culture conditions such as
temperature and/or pH in order to stabilize
and keep cell metabolism at a relatively low
and constant level. At this stage, the perfusion
rate can be reduced to a ﬁxed value, matching
the reduced need of the cells throughout the
production phase.
This article describes such a process based on
the high cell density culture of recombinant CHO
cells in a packed-bed bioreactor, in which perfu-
sion rate was adjusted according to cell growth
requirements during the growth phase and then
pronouncedly reduced during the production
phase without compromising on process produc-
tivity or protein quality.
A ﬁrst-generation process had originally been
designed with the aim to rapidly produce material
for pre-clinical and early clinical trials.
This process was designed with a high perfusion
rate of 2.6 vvd in order to supply the high cell
density (2.5 · 107 cell ml1 of packed-bed) with
fresh medium during production phase. This saved
development time as we avoided spending time to
develop a balanced medium formulation that is
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well adapted to the cell culture needs, and the
product degradation was not a concern since the
high dilution rate imposed to the culture main-
tained a low residence time of our product in the
bioreactor environment.
At a later stage of the development, we investi-
gated a reduction of the medium perfusion rate
by 25% and 50% in order to improve the
economics of this process. A small-scale system
was used to run the tests, and the selected condi-
tions were then implemented at pilot scale in order
to further produce material for clinical trials with
an improved second-generation process.
It is well known that modiﬁcation of the per-
fusion rate during a perfusion process, as well as
modiﬁcation of other bioprocess factors, can
inﬂuence the recombinant protein quality and in
particular its glycosylation pattern (Jenkins et al.
1996; Andersen et al. 2000). Glycosylation is usu-
ally recognized as an important function in the
solubility, immunogenicity, and pharmacokinetic
properties of human glycoproteins and those are
the key parameters in the safety and clinical eﬃ-
cacy of a product (Goochee et al. 1991).
In this study, we used as a model a recombinant
CHO cell line expressing a heavily glycosylated
therapeutical protein for which the purity, N-gly-
can sialylation level, abundance of dimers or
aggregates, were closely monitored in order to
ensure consistent product quality. This model
served as a basis for the study of the impact of a
reduction of the medium perfusion rate on the
process performance and product quality.
Materials and methods
Cell culture – experimental system
A packed-bed bioreactor (Ducommun et al. 2002a,
b) with Fibra-Cel carrier (Bibby Sterilin, UK)
was used to cultivate CHO cells (Laboratoires
Serono, Corsier-sur-Vevey, Switzerland) in a ser-
um free medium (Sigma C-9486). In the small-
scale system that was used to investigate a reduc-
tion of the perfusion rate, the bioreactor and
packed-bed had a working volume of 15 and 5 l,
respectively.
The bioreactor was perfused with 2.6 vvd (as
deﬁned in Table 1) during growth and production
phase. This basic perfusion rate is chosen as the
reference 100%, stated as run-100.
These conditions were applied for all sets of
bioreactor experiments: medium was perfused at
100% during growth phase at 37 C. The tem-
perature was regulated at 37.0 C during growth
phase, and then reduced in two steps down to
32.5 C. The pH was regulated at 7.00 and dis-
solved oxygen concentration (DO) was maintained
at 70% of air saturation throughout the culture.
Due to the fact that counting of cells and cell
number determination in a packed-bed bioreactor
is a complex and inaccurate analysis, we used glu-
cose consumption rate (GCR) as an indirect
method to estimate cell growth and density in the
packed-bed bioreactor. In our system, we have
determined by direct cell counts on a number of
packed-beds cultures that a GCR of 300 g of glu-
cose per kilogram of Fibra-Cel disks per day
corresponds to approximately 2.5 · 107 cells per ml
of packed-bed bioreactor volume (data not shown).
This stage has been deﬁned as the end of the cell
propagation phase at 37 C, and when GCR
reached a level of 300 g of glucose per kilogram of
Fibra-Cel disks per day, the cultures were swit-
ched from 37.0 C to the production mode by
lowering the temperature to 33.5 C. At this stage,
in one set of bioreactors the perfusion was kept at
100% (run-100) and the two other sets were per-
formed with a medium perfusion rate of 75% (run-
75) and 50% (run-50) of the maximal level, as
summarized in Table 1. The temperature was
Table 1. Perfusion rates tested during the production phase for run-100, run-75 and run-50.
Perfusion rate (1 kgFibraCel
1 day1) Dilution rate (vvd*) Replicates (n)
run-100 100±3.5 2.6 .± 0.1 8
run-75 75 2.0 3
run-50 50 1.3 2
Average of n replicates (±2 standard deviations for run-100).
*The dilution rate D expressed in vvd is calculated as litre of medium per litre of total system working volume per day (total volume =
packed-bed + conditioning tank volume).
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further decreased to 32.5 C at a later stage of the
production phase to prevent further cell growth
and to promote production.
In the results section, the bars displayed on the
ﬁgures represent an interval of four standard devi-
ations (±2 standard deviation) measured for the
eight replicates ran under the conditions of run-100.
Assays
Samples were removed daily during the culture.
Glucose and lactate concentrations were quanti-
ﬁed with an EML 105 analyzer (Radiometer
Medical, Brønshøj, Denmark).
The recombinant protein was quantiﬁed with an
ELISA test.
The quality of the recombinant protein was as-
sessed with an RP-HPLC method in combination
with SDS-PAGE methods (ExcelGel SDS Homo-
geneous 12.5% (Cat# 80-1261-01, Pharmacia).
The gels were stained speciﬁcally by Western blot
in order to detect high molecular weight (i.e. di-
mers, aggregates) or low molecular weight variants
of the r-protein. Non-speciﬁc staining by Silver
Stain was also used to assess the relative intensity
of the r-protein compared to impurities after
scanning (Scanner ARCUS 2, Afga) of individual
bands in order to determine their relative intensity.
Protein sialylation, and in particular the abun-
dance of neutral, mono-, di-, tri- and tetra-sialy-
lated N-glycans was analyzed by separation of the
N-glycans according to their charge, as described
by Gervais et al. (2003). The N-glycans were spe-
ciﬁcally cleaved from the r-protein by hydrazinol-
ysis (N-glycanase E-5006B or E-5006C, Glyko
Inc.), labelled with the 2-aminobenzamide ﬂuo-
rescent dye (Signal 2-AB labelling kit K404, Gly-
ko), and separated by a weak anion exchanger
chromatography column (DEAE GlycoSep C,
Glyko) before passing through a ﬂuorescent
detector. The proportions of N-glycans species
could then be determined after integration of the
HPLC peaks corresponding to neutral, mono-, di-,
tri-, and tetra-sialylated forms.
Results
The ﬁrst attempt was to reduce the perfusion rate
from 2.6 to 2.0 vvd and 1.3 vvd during the produc-
tion phase (Figure 1) and to follow its eﬀect on cell
metabolism, volumetric productivity and product
quality.
The concentration of glucose and lactate were
measured for all three perfusion rates (Figure 2),
and the residual glucose level remained above
0.5 g/l.
The results in Figure 3 show the GCR levels for
the three sets of medium perfusion rate tested.
These results indicate that a reduced perfusion rate
Figure 1. Medium perfusion rate during continuous cultures of
CHO cells in a packed-bed bioreactor, with perfusion levels of
2.6 vvd (d), 2.0 vvd (s) and 1.3 vvd (m). The bioreactor runs
have been labelled as run–100 for 100% perfusion (d), run–75
for 75% perfusion (s) and run–50 for 50% perfusion (m). The
maximum perfusion rate of 100% corresponds to 2.6 vvd that
were used as the reference conditions.
Figure 2. Glucose (a) and lactate (b) concentration proﬁles
during continuous cultures of CHO cells in a packed-bed bio-
reactor, for medium perfusion rates of 100% (d) 75% (s) and
50% (m).
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induces a lower GCR of the culture. However, this
eﬀect was barely signiﬁcant and when the medium
perfusion rate was reduced by 25% and 50%,
the average GCR measured over the 60-day pro-
duction phase were reduced by 8% and 15%,
respectively (Figure 3).
In parallel, the apparent molar ratio (Figure 4)
of glucose conversion to lactate Ylac/glc slightly
decreased in response to lower perfusion rate but
remained in a range of 1.55–1.65 mole of lactate
produced per mole of glucose consumed. The dif-
ferences observed for the Ylac/glc ratio were not
statistically signiﬁcant since all data points mea-
sured for the test runs at reduced perfusion rate are
comprised within ±2 standard deviations of val-
ues obtained with the reference runs.
Process productivity
The results presented in Figure 5 show a com-
parison of the recombinant protein produced
(volumetric productivity, total production, and
titre) in the reference run-100 and in the runs with
reduced medium perfusion.
When the medium perfusion rate was reduced by
25% and 50%, the average volumetric pro-
ductivity was reduced by 3% and 30%,
respectively (Figure 5a). The lower productivity
result obtained for run-50 are statistically diﬀerent
from the reference conditions.
Another diﬀerence observed in Figure 5a is the
decline of the volumetric productivity over time
along the production phase. A stable volumetric
Figure 4. Apparent lactate from glucose molar conversion ratio
proﬁle during continuous cultures of CHO cells in a packed-bed
bioreactor, for medium perfusion rates of 100% (d) 75% (s)
and 50% (m).
Figure 5. Normalized productivity data (a) volumetric pro-
ductivity in units of product per total culture volume per day,
(b) cumulated product in units of product, (c) titre in units of
product per total culture volume, for a r-protein which is pro-
duced during continuous cultures of CHO cells in a packed-bed
bioreactor, for medium perfusion rates of 100% (d) 75% (s)
and 50% (m). To normalize the data, the average value ob-
tained at 100% perfusion rate over the 60-day production phase
was taken as 100% productivity (dotted line).
Figure 3. Glucose consumption rate (GCR) proﬁle during
continuous cultures of CHO cells in a packed-bed bioreactor,
for medium perfusion rates of 100% (d) 75% (s) and 50%
(m). GCR is expressed in grams of glucose consumed per day
and per kg of Fibra-Cel carrier.
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productivity was observed for run-100 and run-75,
but in run-50 productivity declined over the
duration of the 60-day production phase. More
speciﬁcally, the productivity level of run-50 was
only 60% of the reference value at the end of the
60-day production phase.
The lower productivity of run-50 is also shown
on Figure 5b, which represents the cumulated
amount of product made over the 60-days pro-
duction phase.
The corresponding titres measured for the dif-
ferent perfusion rates are presented in Figure 5c,
which shows that recombinant protein titres were
increased by +25% and +50%, respectively as
opposed to the control when the perfusion was
decreased by 25% and 50%.
Product quality
With the reduction of the perfusion rate from 2.6
to 2.0 vvd and 1.3 vvd that was tested for run-100
run-75 and run-50, the residence time (s) of the
recombinant protein was increased from 0.4 to 0.5
and 0.8 day respectively (s = 1/D).
As longer exposure to the environment in the
bioreactor could potentially lead to a degradation
of the recombinant protein, a preliminary stability
study was done before initiating the tests in bior-
eactors. A puriﬁed sample of the r-protein was
spiked into cell culture medium, and the quality
attributes of the r-protein were monitored after 1,
2 and 5 days of incubation at 37 C. Since no sign
of product degradation was detected by the sta-
bility indicating method (data not shown), it was
decided to proceed with the bioreactor experi-
ments.
During the tests in bioreactors, the recombinant
protein was puriﬁed to homogeneity at three
points of the bioreactor runs (day 20, 40 and 60) in
order to verify that the product quality was
maintained for each perfusion rate investigated.
The conditions of run-50 were considered as a
worst case for protein degradation since this run
had the lowest perfusion rate and the longest
product residence time in the bioreactor.
To evaluate if product quality was aﬀected by
the reduced perfusion rate, ﬁnal bulks of run-50
were analyzed by SDS-PAGE Silver Stain and
SDS-PAGE Western blot, and compared to the
proﬁle obtained in the reference conditions of run-
100. The corresponding data obtained for one bulk
produced with r-protein harvested at days 47 and
48 of the production phase of run-50 are presented
in Figures 6 and 7. No modiﬁcation of the r-pro-
tein quality attributes was detected for run-50
compared to run-100. The electrophoretic purity
measured by SDS-PAGE Silver Stain in Figure 6
was higher than 99% purity for all lanes, and no
presence of aggregates or truncated forms could be
detected as shown on the SDS-PAGE Western
blot in Figure 7.
The high level of purity 100% of the r-protein
produced was conﬁrmed by RP-HPLC for run-
100, run-75 and run-50. Finally, the amount of
impurities derived from the host CHO cell (Host
Cell Proteins) in the puriﬁed protein was quanti-
ﬁed by HCP-ELISA (data not shown) and was
found consistent among run-50, run-75 and run-
100.
Samples of the recombinant protein of interest
were also submitted to N-glycan mapping in order
to quantify the proportion of the diﬀerent sialy-
lated forms of the protein of interest. The N-glycan
mapping results summarized in Table 2 show that
comparable proportions of N-glycans are obtained
for all perfusion rates tested. This is also illustrated
Figure 6. Electrophoretic purity by SDS-PAGE Silver Stain
method. Lane 1: molecular weight markers. Lanes 2, 3, 4: ﬁnal
bulk obtained at 50% perfusion rate (run-50) at production day
47–48 analyzed in triplicate; Lane 5: reference material obtained
at 100% perfusion rate (run-100); Lane 6: BSA 5%; 7: BSA 2%;
8: BSA 1%.
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by the corresponding HPLC proﬁles reported in
Figure 8.
A comparison of these data demonstrates that
the product sialylation is not altered under con-
ditions of reduced perfusion rate, and the data
obtained for run-75 and run-50 are clearly within
the range obtained under the standard conditions
of run-100.
Discussion
The results show that the strategy to ﬁx the per-
fusion rate at a deﬁned value allows the system to
stabilize and to operate at quasi steady state over
the 60-days production phase at 33.5/32.5 C, this
is conﬁrmed by the glucose and lactate levels
(Figure 2) that are maintained at a stable level
throughout the production phases in run-100, run-
75 and run-50. During the development of a
perfusion process producing EPO, it was also
observed that a constant perfusion rate allowed
the system to approach steady state, in which the
concentration of the main components were
maintained at a constant level (Wang et al. 2002).
The reason for a lower GCR observed under
lower perfusion rate was investigated. This phe-
nomenon was already characterized in a similar
packed-bed culture where a reduction of the cel-
lular speciﬁc glucose consumption was measured
Figure 7. Electrophoretic purity by SDS-PAGE Western blot
method. Lane 1: molecular weight markers. Lanes 2, 3, 4: ﬁnal
bulk obtained at 50% perfusion rate (run-50) at production day
47 and 48 analyzed in triplicate; Lane 5: reference material
obtained at 100% perfusion rate (run-100). Lane 6: molecular
weight markers.
Table 2. Fraction of diﬀerently sialylated N-glycan molecules (given as % of the N-glycan groups) in semi-puriﬁed samples of drug
substance for run-100, run-75 and run-50.
Fraction of diﬀerently sialylated N-glycan molecules
Neutrals (%) Mono-sialylated (%) Di-sialylated (%) Tri-sialylated (%) Tetra-sialylated (%)
Run-100 19–21 21–29 39–44 7–11 2–4
Run-75 18–22 20–23 44–50 8–9 3–4
Run-50 19–21 20–25 45–48 8–10 2–4
Figure 8. Sialylation by N-glycan mapping (RP-HPLC proﬁles)
in intermediate bulk samples at production day 47 and 48 of
run-50, run-75 and run-100.
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when the temperature was decreased to 33.5/
32.5 C (Ducommun et al. 2002b). The hypothesis
that it could be due to cell loss under lower per-
fusion was ruled out by the fact that the cell den-
sity in suspension in the cell culture medium was
always below 0.1 · 106 cell ml1 in all runs, which
indicates that very few cells detached from the
packed-bed over the duration of the runs.
Similar studies were made by Hiller and Miller,
where they analyzed the metabolic response of
hybridoma cells after changes in dilution rate
(Miller et al. 1988; Hiller et al. 1991). When the
dilution rate was decreased from 1.0–1.3 to 0.3–
0.4 day1 the ratio Ylac/glc decreased from 1.9–2.1
to 1.6 at lower perfusion rate. The response of
Ylac/glc to variation in the perfusion rate is not al-
ways so marked, and Banik and Heath (1996)
observed with another hybridoma cell line that
Ylac/glc was constant in a range of 1.39–1.41 and
was unaﬀected by changes in perfusion rates.
In this study, the Ylac/glc ratio was not signiﬁ-
cantly modiﬁed at 25% or 50% perfusion rate
since all data points measured for the test runs
were comprised within ±2 standard deviations of
values obtained for the reference runs.
As the cellular metabolism remained unchanged
under reduced perfusion conditions, one could ex-
pect the cellular productivity of the r-protein to be
maintained as well. This was in fact observed, and
the volumetric productivity was maintained (3%)
compared to the reference process when the per-
fusion rate was reduced by 25%. But when the
perfusion was further reduced by 50% of its
original level, the productivity dropped by 30%.
In the conditions of run-50, the lower produc-
tivity obtained might either be linked to the
depletion of a key substrate present in the cell
culture medium (amino acids, vitamins, etc.) or to
the inhibition of one of typical by-products (such
as lactate or ammonia), two major causes of pro-
ductivity loss commonly reported under low per-
fusion conditions (Kurokawa et al. 1993).
To investigate this question, de la Broise et al.
submitted a culture of suspension hybridoma cells
secreting IgM to variations of perfusion rate, while
the cells were fully retained in the bioreactor sys-
tem by tangential-ﬂow ﬁltration (de la Broise et al.
1991). After equilibrium, the dilution rate was in-
creased from 0.5 to 1.0 vvd, but the available
substrates (nutrients and growth factors) were
maintained constant by the use of a standard
medium half-diluted in an osmotic salt solution.
No signiﬁcant eﬀect on the cell density or viability
was observed and the IgM concentration in the
ﬁltrate was reduced by nearly half indicating that
IgM production rate was also kept nearly con-
stant. Those results showed that in their system,
the substrate availability rather than a toxic eﬀect,
was the main factor driving the antibody produc-
tion rate.
A similar study was conducted with hybridoma
cells producing an antibody product (Banik and
Heath 1996). The cells were totally retained in the
cell culture system by a microﬁltration module,
while the perfusion rate was varied. Diﬀerent rates
of medium supply and waste removal were applied
(2.5, 1.5 and 0.75 vvd) to determine whether cell
density was limited or inhibited, and whether a
substance could be responsible for the correlation
between cell density and productivity of an anti-
body product. The authors found that in that case,
nutrients supply was a stronger determinant of cell
density than waste removal.
In another study (Racher and Griﬃths 1993),
the dilution rate had also to be increased from 0.3
to 1.0 vvd to avoid limitations and maximize
density of BHK 21 cells expressing a recombinant
antibody in order to reach a higher volumetric
productivity in a ﬁxed-bed bioreactor system.
This clearly conﬁrms that the optimal perfusion
level has to be chosen carefully in order to realize
signiﬁcant medium savings without compromising
on productivity (Pinton et al. 1991; Schmid et al.
1992).
In our case, the data available do not allow us to
conclude on the reason (inhibition or limitation)
for the 30% loss of productivity that was ob-
served when the perfusion rate was reduced
by 50%. However, from the literature examples
given above, it can be expected that the drop in
productivity is most probably due to a limitation
of one or more components of the cell culture
medium.
Another property that may be inﬂuenced by a
modiﬁcation of the perfusion rate is the product
quality. A modiﬁcation of the dilution rate (D) will
change the environmental culture conditions as
well as the average residence time (s) of the r-
protein of interest in the bioreactor, and for some
proteins that are sensitive to degradation, the
perfusion rate cannot be reduced without com-
promising product quality.
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For example, recombinant factor VIII is very
sensitive to proteolytic degradation and its pro-
duction process operates with a high medium re-
newal rate of 6–8 vvd in order to ensure a short
residence time (s = 3–4 h) of the product in the
bioreactor (Chuppa et al. 1997). The same authors
also demonstrated that the protein activity is
maximized when a high dilution rate is combined
with a reduction of the temperature from 37 C to
34–35 C since the proteolytic activity of key
degrading enzymes can be reduced at lower tem-
perature.
Another case of enzymatic degradation was re-
ported for recombinant human IFN-c (Goldman
et al. 1998). The authors showed that the sialyla-
tion of glycans of rhIFN-c was consistent
throughout a ﬂuidized-bed perfusion culture,
whereas the sialylation declined signiﬁcantly in the
stationary and death phase of a comparable batch
culture most likely due to the activity of sialidases
released from lysed cells.
A similar observation was made for the glyco-
sylation pattern of a MAb product (Mohan et al.
1993). The MAb was found incompletely gly-
cosylated in batch cultures or in perfusion cultures
operated with 0.36 vvd medium renewal rate, and
the perfusion rate had to be increased to 0.60 vvd
in order to generate fully glycosylated MAb.
Finally, it was also reported for the production
of b-secretase from suspension cultures of HEK-
293 cells that the highest speciﬁc activity was ob-
tained with the highest dilution rate tested (2 vvd),
compared to the other conditions applied: 1 vvd,
0.5 vvd and batch culture (Lu¨llau et al. 2003).
In this study, it was important to evaluate that
the product quality was maintained upon reduc-
tion of the medium perfusion rate. The run with
the lowest perfusion, run–50, has the longest resi-
dence time (s=0.8 day) and this is the worst case
for protein stability since it leaves the product
exposed to all degrading activities present in the
bioreactor environment for the longest time. Un-
der these conditions we can consider that 99% of
the protein will have a residence time in the bio-
reactor system shorter than 4 day (5s= 4 day for
run-50).
Since the stability study demonstrated that the r-
protein could be stored for up to 4 days at 37 C in
crude harvest without signiﬁcant alterations, it was
anticipated that under the range of perfusion rates
tested the product would not be degraded. This
was conﬁrmed by the results obtained in the bio-
reactor runs, as all lots of puriﬁed protein gener-
ated at production day-20, day-40 and day-60 of
each perfusion conditions tested met the speciﬁ-
cations established with reference material from
run-100. So in our study reported here, no sign of
product degradation could be detected.
Glucose starvation is also a typical cause of
incorrect product sialylation (Goochee and
Monica 1990). This eﬀect has been studied for
IFN-c produced from CHO cells, and the product
glycosylation was found aﬀected under low glu-
cose residual levels below 0.1 g/l (Hayter et al.
1993; Hooker et al. 1995).
In the conditions reported here, the r-protein
sialylation was not aﬀected due to the lower glu-
cose concentrations (Figure 2) reached during the
production phase of run-75 and run-50. This can
be explained by the fact that the range of residual
glucose concentrations (2.6–0.5 g/l) reported here
is still much higher than the value of less than
0.1 g/l glucose level (probably inducing some glu-
cose starvation eﬀect) for which incomplete sialy-
lation of IFN-c was observed.
Based on the results obtained at small-scale, a
reduction of 25% medium perfusion was imple-
mented at pilot scale in the second-generation
process, which enabled to maintain the same pro-
ductivity and the same quality of the molecule,
while reducing costs of media, material and man-
power of the production process.
The 25% reduction on medium translated di-
rectly into a 25% saving on: the powder medium
and side ingredients, the pre-ﬁlters and sterilizing
ﬁlters, the sterile bags used for media storage after
ﬁltration, and the labour costs associated with
medium preparation as fewer medium batches
were needed.
As the r-protein titre in the crude harvest was
increased by +25% in the second-generation
process, the downstream processing beneﬁted from
similar savings: reduced manpower needs due to
smaller volumes to handle, reduced puriﬁcation
cycle time, optimization of the equipment and
manpower needs, etc (data not shown).
Conclusion
From the results obtained at small-scale it is clear
that reduction of 25% in perfusion rate
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combined both beneﬁts of maximizing productiv-
ity with a saving of 25% on medium consump-
tion.
Further reduction of the perfusion rate to 50%
was detrimental to the process productivity, which
declined by 30% under such conditions. Also,
with the 50% perfusion rate conditions, volu-
metric productivity declined over the duration of
the 60-day production phase, whereas a stable
productivity was maintained with the higher per-
fusion rates tested.
The implementation of 25% perfusion in our
routine pilot scale production runs simpliﬁed the
operations of both upstream and downstream
units, and allowed signiﬁcant savings on the cost
of goods of this production process.
For industrial applications, it is recommended
to test whether and how far the perfusion rate can
be decreased during the production phase – pro-
vided that the product is not sensitive to residence
time – with the aim to reduce cost of goods and to
simplify manufacturing operations.
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